

proliferation signal blockage.<sup>1</sup> Although the pathogenesis is still unclear, the uraemic toxins accumulated in the CKD may suppress both cellular and humoral immunity.<sup>8</sup> Nevertheless, despite the known association between chronic inflammation and KS other malignancies are more prominent in dialysis patients.<sup>9</sup> However, chronic inflammation caused by chronic venous stasis (CVS) may contribute to the development of KS in stasis area.<sup>10</sup> As in our case, in previously submitted two cases KS is accompanied with venous stasis and this supports this data.<sup>4</sup>

As a result, in the extremity where AVF exists, HHV-8 and KS existed together. The inflammation and immunosuppression in CKD may contribute to the development and progression of KS.

#### REFERENCES

- Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. *J Am Acad Dermatol.* 2008;59:179–206.
- Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science.* 1994;266:1865–9.
- Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. *Clin J Am Soc Nephrol.* 2008;3:1526–33.
- Lee D, Chun JS, Hong SK, Kang MS, Seo JK, Koh JK, et al. Kaposi sarcoma in a patient with chronic renal failure undergoing dialysis. *Ann Dermatol.* 2013;25:475–8.
- Herr H, Kim JU, Kang GH, Moon KC, Koh JK. Kaposi's sarcoma occurring during short-term dialysis: report of two cases. *J Korean Med Sci.* 2001;16:130–4.
- Schwartz RA. Kaposi's sarcoma: advances and perspectives. *J Am Acad Dermatol.* 1996;34:804–14.
- Akinde O, Obadofin O, Adeyemo T, Omoseebi O, Ikeri N, Okonkwo I, et al. Kaposi sarcoma among HIV infected patients in Lagos University Teaching Hospital, Nigeria: a 14-year retrospective clinico pathological study. *J Skin Cancer.* 2016;2016:9368023.
- Raska K Jr, Raskova J, Shea SM, Frankel RM, Wood RH, Lifter J, et al. T cell subsets and cellular immunity in end-stage renal disease. *Am J Med.* 1983;75:734–40.
- Rancho JA, Zarrabeitia MT, de Francisco AL, Amado JA, Napal J, Arias M, et al. Vitamin D therapy modulates cytokine secretion in patients with renal failure. *Nephron.* 1993;65:364–8.
- Pappas PJ, Teehan EP, Fallek SR, Garcia A, Araki CT, Back TL, et al. Diminished mononuclear cell function is associated with chronic venous insufficiency. *J Vasc Surg.* 1995;22:580–6.

Baris Eser, Ozlem Yayar, Ibrahim Dogan, Yilmaz Bas

Hitit University Corum Training and Research Hospital, Corum, Turkey

E-mail address: [beser374@gmail.com](mailto:beser374@gmail.com) (B. Eser).

2013-2514/© 2017 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <http://dx.doi.org/10.1016/j.nefro.2017.09.008>

## Calcimimetics have had no impact on the indications for surgery of tertiary hyperparathyroidism<sup>☆</sup>

### Los calcimiméticos no han tenido impacto en la cirugía del hiperparatiroidismo terciario

Dear Editor,

Tertiary hyperparathyroidism (THPT) occurs in 2–25% of renal transplant patients with normal renal function. THPT is due to the autonomous proliferation of the parathyroid glands.<sup>1,2</sup> Hypercalcemia impairs renal function through vasoconstriction and causes tubulointerstitial calcifications, which limits long-term graft survival.<sup>3</sup> Therefore, early treatment of


hypercalcemia is important to prevent deterioration of renal graft function.

Until year 2005, when calcimimetics became available, surgical treatment of THPT was the only effective strategy to control hypercalcemia in renal transplant patients.<sup>3,4</sup> The calcimimetic, cinacalcet controls hypercalcemia without affecting renal function.<sup>5,6</sup> However, while cinacalcet reduces the need for parathyroidectomy in patients with severe

DOI of original article:

<http://dx.doi.org/10.1016/j.nefro.2016.10.021>.

<sup>☆</sup> Please cite this article as: Ruiz J, Ríos A, Rodríguez JM, Llorente S, Jimeno L, Parrilla P. Los calcimiméticos no han tenido impacto en la cirugía del hiperparatiroidismo terciario. *Nefrologia.* 2017;37:651–653.



**Fig. 1 – Percent of kidney transplant patients with acceptable renal function who undergo parathyroidectomy for treatment of tertiary hyperparathyroidism as a function of the study period (pre and post cinacalcet).**

secondary hyperparathyroidism,<sup>7</sup> in the tertiary this beneficial effect has not been confirmed.<sup>5,6</sup>

The objective of the study is to analyze the impact that cinacalcet has had on parathyroidectomies for the treatment THPT in our center after 10 years of use.

The study included renal transplant patients with normal renal function who required parathyroidectomy between January 1995 and December 2014. Cases with prior thyroid and/or parathyroid surgery and those with syndrome of MEN were excluded. For the analysis of the data, two periods are differentiated separated by the introduction of cinacalcet in our center: (1) pre-cinacalcet period: 1995–2004; and (2) post-cinacalcet period: 2005–2014. In THPT surgery was performed in cases with hypercalcemia that did not respond to conservative measures. Both groups differ in the use of cinacalcet prior to surgery. Epidemiological, clinical, therapeutic and follow-up variables are analyzed. For statistical analysis, the SPSS 15.0<sup>®</sup> software for Windows<sup>®</sup> is used, using the chi-squared test, the Fisher exact test, the Student's t-test and the Mann-Whitney U test.

Selection criteria were fulfilled by 24 kidney transplant recipients, with a mean age of  $47.9 \pm 8.2$  years, 66.7% ( $n=16$ ) were male. Twenty three patients (95.8%) were on hemodialysis and one (4.2%) was on peritoneal dialysis, with a mean time of  $6.6 \pm 5.3$  years prior to receiving the last transplant. 33.3% ( $n=8$ ) received more than one kidney transplant. The mean time from renal transplantation to parathyroidectomy was  $37 \pm 32.3$  months (3–115 months).

Fifty-four percent of patients ( $n=13$ ) were parathyroidectomized during the pre-cinacalcet period and the remaining 46% ( $n=11$ ) during post-cinacalcet ( $p>0.05$ ). Regarding the total number of kidney transplant patients with acceptable renal function per year, parathyroidectomy was performed in 1.3% of patients per year during pre-cinacalcet period as compared with a 1% in the post-cinacalcet period ( $p>0.05$ ) (Fig. 1).

Comparison of patients from the pre and post cinacalcet era shows that there were no differences in the variables

analyzed, except for Two. First all patients ( $n=13$ ) receiving parathyroidectomy during the post-cinacalcet period were asymptomatic compared to  $n=7$  patients (34%) in the pre-cinacalcet period ( $p=0.016$ ). Most symptomatic patients had pain in bone and joints. The second difference was the serum phosphorus concentration, which was lower in the post-cinacalcet than pre-cinacalcet group ( $2.3 \pm 0.2$  mg/dl versus  $2.8 \pm 0.4$  mg/dl;  $p=0.011$ ). In all cases, the surgical treatment was subtotal parathyroidectomy. There was a reoccurrence of THPT in 4.2% in the pre-cinacalcet group, which is now controlled with cinacalcet t.

As opposed to what is being described regarding secondary hyperparathyroidism, with approval of cinacalcet by the European Medication Agency, there has been no decrease in the number of indications for parathyroidectomy in THPT. However, we have observed that patients on cinacalcet are asymptomatic at the time of surgery. Thus both treatments improve patient's quality of life.

If surgery is required, subtotal parathyroidectomy shows very acceptable results with low recurrence rates if performed in endocrine surgical units with experience.<sup>8</sup>

In conclusion, cinacalcet has not been able to reduce the surgical indications of THPT, although patients with surgical indication have fewer symptoms.

## REFERENCES

1. Yang RL, Freeman K, Reinke CE, Fraker DL, Karakousis GC, Kelz RR, et al. Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. *Transplantation*. 2012;94:70–6.
2. Kebebew E, Duh Q, Clark O. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. *Arch Surg*. 2004;139:974.
3. Torregrosa JV, Barros X. Management of hypercalcemia after renal transplantation. *Nefrología*. 2013;33:751–7.
4. Triponez F, Clark OH, Vanrenthergem Y, Evenepoel P. Surgical treatment of persistent hyperparathyroidism after renal transplantation. *Ann Surg*. 2008;248:18–30.
5. Cohen JB, Gordon CE, Balk EM, Francis JM. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. *Transplantation*. 2012;94:1041–8.
6. Paschoalin RP, Torregrosa JV, Sánchez-Escuredo A, Barros X, Durán CE, Campistol JM. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. *Transplant Proc*. 2012;44:2588–9.
7. Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes LC, et al. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. *Ren Fail*. 2016;38:857–74.
8. Zambudio AR, Rodríguez J, Riquelme J, Soria T, Canteras M, Parrilla P. Prospective study of postoperative complications after total thyroidectomy for multinodular goiters by surgeons with experience in endocrine surgery. *Ann Surg*. 2004;240:18–25.